Apoptosis-like cell death in *Leishmania donovani* treated with KalsomeTM10, a new liposomal amphotericin B

Md. Shadab, Baijayanti Jha, Mohammad Asad, Makaraju Deepthi, Mohd. Kamran, Nahid Ali*

Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Jadavpur, Kolkata, West Bengal, India

* nali@iicb.res.in

Abstract

**Objective**

The present study aimed to elucidate the cell death mechanism in *Leishmania donovani* upon treatment with KalsomeTM10, a new liposomal amphotericin B.

**Methodology/Principal findings**

We studied morphological alterations in promastigotes through phase contrast and scanning electron microscopy. Phosphatidylserine (PS) exposure, loss of mitochondrial membrane potential and disruption of mitochondrial integrity was determined by flow cytometry using annexinV-FITC, JC-1 and mitotraker, respectively. For analysing oxidative stress, generation of H$_2$O$_2$ (bioluminescence kit) and mitochondrial superoxide O$_2^-$ (mitosox) were measured. DNA fragmentation was evaluated using terminal deoxyribonucleotidy l transferase mediated dUTP nick-end labelling (TUNEL) and DNA laddering assay. We found that KalsomeTM10 is more effective then Ambisome against the promastigote as well as intracellular amastigote forms. The mechanistic study showed that KalsomeTM10 induced several morphological alterations in promastigotes typical of apoptosis. KalsomeTM10 treatment showed a dose- and time-dependent exposure of PS in promastigotes. Further, study on mitochondrial pathway revealed loss of mitochondrial membrane potential as well as disruption in mitochondrial integrity with depletion of intracellular pool of ATP. KalsomeTM10 treated promastigotes showed increased ROS production, diminished GSH levels and increased caspase-like activity. DNA fragmentation and cell cycle arrest was observed in KalsomeTM10 treated promastigotes. Apoptotic DNA fragmentation was also observed in KalsomeTM10 treated intracellular amastigotes. KalsomeTM10 induced generation of ROS and nitric oxide leads to the killing of the intracellular parasites. Moreover, endocytosis is indispensable for KalsomeTM10 mediated anti-leishmanial effect in host macrophage.
Conclusions

Kalsome TM10 induces apoptotic-like cell death in *L. donovani* parasites to exhibit its anti-leishmanial function.

Introduction

Leishmaniasis, a vector borne parasitic disease, is prevalent in 98 countries with 350 million people at a risk of infection [1]. Disease manifestations include visceral, cutaneous and mucocutaneous forms. Visceral leishmaniasis (VL, also known as kala-azar), caused by *L. donovani* and *L. infantum* in Old World and *L. chagasi* in New World, is often deadly if left untreated [2]. Currently, there is no anti-leishmanial vaccine and control measures rely on few conventional drugs. Pentavalent antimonials that have been the torch bearers in the treatment of VL are not free from toxicity (nephro- and hepato-), and associated side effects of long term intravenous injections. Furthermore, the emergence of resistant parasites has worsened the scenario of VL therapy [3]. Amphotericin B, a polypeptide macrolide, is the best drug available for the treatment of kala-azar and is effective in curing patients also infected with antimony resistant parasites. However, it remains a second-line drug due to its severe toxicities. Moreover, since the drug is administered parenterally through long term hospitalization the overall cost of treatment increases. Hence, to ameliorate these problems, lipid formulations of amphotericin B including liposomal amphotericin B (L-AmB (Ambisome)), colloidal dispersion of amphotericin B (ABCD (Amphotec)) and amphotericin B lipid complex (ABLC (Abelcet)) were developed [4]. These lipid formulations offered a much higher treatment efficacy with comparatively shorter duration of administration, reducing the cost of hospitalization significantly. However, one of the major drawbacks associated with these formulations is that they entrap small amounts of amphotericin B, thereby increasing the dose of administration for efficient cure. This in turn not only increases the cost as amphotericin B is itself quite costly, but also increases the risk of lipid associated side effects. Moreover, treatment failure of Ambisome in AIDS patients co-infected with VL (by *L. infantum*) in Europe [5], in below 5 years aged children infected with Brazilian VL (due to *L. chagasi*), in Indian kala-azar [6] and recently in Sudanese patients of VL is worrisome [7]. Therefore, new lipid formulations of amphotericin B are in need to overcome these drawbacks. To address some of these issues, Kalsome TM10, a new liposomal formulation of amphotericin B has recently been developed [8]. It offers an advanced alternative option wherein the drug is packaged with ergosterol, in place of cholesterol, which provides a much greater binding affinity (nearly > 8 folds) to amphotericin B and thus facilitates its higher loading in a smaller amount of liposome. This reduces not only the toxicity but also the dose of the drug as well as the amount of liposome required for entrapping the drug, thereby lowering the overall cost significantly.

The in vivo toxicity and anti-leishmanial efficacy of Kalsome TM10 have already been tested and the results showed that the toxicity of amphotericin B was almost negligible, when the drug was used in the liposomal form, compared to the deoxycholate form (Fungizone) [9]. Moreover, Kalsome TM10 showed almost complete clearance of parasites in infected BALB/c mice, which was correlated with enhanced Th1 response and suppressed Th2 response [8]. Taken together, these results confirm that Kalsome TM10 is efficacious against in vivo model of murine VL with no major toxic effects. However, the actual mechanism of action of Kalsome TM10 on *Leishmania* parasites is yet not clear. Given the recent emergence of amphotericin B resistant parasites [10], it would be of interest to investigate the relevant cell death mechanisms associated with this formulation.
mechanism in KalsomeTM10 treated *L. donovani*, so that these could be used as a tool to estimate the changing susceptibility of these parasites to amphotericin B and its liposomal formulations. The information gained from the mechanistic study of killing would allow development of effective anti-leishmanial interventions against the parasites and those showing a kind of resistance to amphotericin B.

In this study we did not used empty liposome owing to its no activity in vivo model of VL [9]. We showed here that KalsomeTM10 induces effective clearance of parasites in infected host macrophages at doses significantly lower than that induced by amphotericin B and Ambisome. In addition, we showed that the leishmanicidal effect of KalsomeTM10 is a consequence of induction of apoptotic-like cell death in promastigotes as well as intracellular amastigotes. We report that the KalsomeTM10 treated parasites demonstrated numerous cytoplasmic, nuclear, and membrane features that resembles to that of the apoptotic metazoan cells. These include cell shrinkage, DNA fragmentation into oligonucleosome-sized fragments, phosphatidylserine exposure and mitochondrial dysfunction etc. All the above features are the characteristic events of the cells in the early phase of apoptosis. All together, our results show that KalsomeTM10 induces apoptotic-like cell death in *L. donovani* parasites.

**Materials and methods**

**Ethics statement**

The study was approved by and carried out under the guidelines of the Ethical Committee of the Indian Institute of Chemical Biology, Kolkata. All subjects who participated in this study provided informed consent in writing according to the Indian Institute of Chemical Biology guidelines and approval. The animal experiments were approved by the Animal Ethical Committee (147/1999/CPSCEA) of the institute, according to the National Regulatory Guidelines issued by the Committee for the Purpose of Control and Supervision on Experimental Animals (CPCSEA), under the Division of Animal Welfare, Ministry of Environment and Forest, Government of India.

**Animals and parasite**

BALB/c mice, bred in the animal house facility of Indian Institute of Chemical Biology (Calcutta, India), were used for the experiments. For parasite maintenance the *L. donovani* strain AG83 (MHOM/IN/1983/AG83), originally isolated from an Indian kala-azar patient was periodically injected in appropriate numbers in 4–6 weeks old Syrian golden hamsters (*Mesocricetus auratus*) reared in pathogen-free animal care facility of the Indian Institute of Chemical Biology. The infected hamsters were sacrificed at two months infection to isolate *L. donovani* amastigotes from the spleens. These amastigotes were transformed into promastigotes in M199 supplemented with 10% FCS, 2 mM glutamine, penicillin G (100 U/ml) and streptomycin sulfate (100 μg/ml) at 22˚C.

**Reagents**

RPMI 1640, M199, penicillin, streptomycin, PEG-Catalase (PEG-Cat) and PEG-Superoxide dismutase (PEG-SOD) were purchased from Sigma Chemical Co. (St Louis, MO, USA). Fetal calf serum (FCS) was from (GIBCO/BRL, Grand Island, NY). N-Acetyl-L-cysteine (NAC) and NG-monomethyl L-arginine (L-NMMA) was purchased from Merck (GmbH, Germany). MitoTracker deep red and MitoSOX™ red were obtained from Molecular Probes (Eugene, OR, USA). The new formulation of liposomal amphotericin B, Kalsome™10, was a kind gift from Lifecare Innovations Pvt. Ltd. Gurgaon, India. Conventional liposomal formulation of AmB
(Ambisome) was purchased from Gilead Science, Inc., (USA). Amphotericin B deoxycholate was purchased from Bharat Serums and Vaccines Limited (India).

**Formulation of KalsomeTM10 and Ambisome**

KalsomeTM10 is a sterol enriched, mixed lamellarity, amphotericin B intercalating liposome in 0.9% saline, wherein, the concentration of amphotericin B is 0.2 mg/mg total lipid. Ergosterol constitutes almost 50% of the total liposomal lipid, overall consisting of phosphatidylcholine, ergosterol and AmB in 5:2:1.8 molar ratios [8].

Ambisome is unilamellar bilayer liposome with amphotericin B intercalated within the membrane wherein, the concentration of amphotericin B is 0.143 mg/mg total lipid [11].

**Nanoparticle Tracking Analysis (NTA)**

NTA measurements were done with a NanoSight LM20 (NanoSight, Amesbury, United Kingdom), according to the recommended protocol using appropriate dilutions of KalsomeTM10 and Ambisome. The software used for capturing and analyzing the data was the NTA 2.0 Build 127. The mean size and SD values were obtained using the NTA software. These values correspond to the arithmetic values calculated with the sizes of all the particles analyzed by the software.

**Cell viability assay**

AlamarBlue® reagent (Life Technologies, Carlsbad, USA) was employed for *L. donovani* promastigote and mouse peritoneal macrophage cell viability assay. Live cells maintain a reducing environment within their cytosol. AlamarBlue® reagent contain Resazurin/AlamarBlueH (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) as an active ingredient which is non-toxic and cell permeable. This active compound is blue in colour and virtually non-fluorescent. Upon entering cells, resazurin is reduced to resorufin which is red in colour and highly fluorescent. Hence, viable cells continuously convert resazurin to resorufin thereby increasing the overall fluorescence and colour of the media surrounding the cells. Assays were performed in sterile 96-well plates using 100 μl of late log-phase promastigotes adjusted to (1x10⁷ cells/ml) and 5x10⁵ macrophages in 100 μl of medium. These cells were incubated in the absence (control) or presence of varying concentrations of KalsomeTM10, Ambisome and amphotericin B for different time periods. After the completion of treatment, 10 μl of the resazurin dye (0.01%) was added to these cells, and were incubated for a further 4 h at 37˚C. We have seen that culturing the promastigotes at 37˚C for 4 h does not affect the viability of the parasites as also shown by an earlier report [12]. Cells were then analyzed in a MicroQuant microplate reader (Biotek-Instrument Inc., Winooski, VT, USA) at a wavelength of 570 nm, using 600 nm as reference wavelength (normalized to the 600 nm value). Cell viability was evaluated based on comparison with untreated control cells. ED₅₀ and ED₉₀ defined as the KalsomeTM10 concentrations that inhibited resazurin reduction with respect to control parasites by 50% and 90%, respectively, were calculated using sigmoidal regression analysis (Microsoft Excel).

**Determination of cellular morphology in *L. donovani* promastigotes**

*L. donovani* promastigotes (1×10⁷ cells/ml) were treated with different concentrations of KalsomeTM10, and incubated at 22±2˚C for 4 h. The cells were then harvested, resuspended in PBS (pH 7.4), and observed under optical microscope (Laika DMI 4000, Leica and Zeiss Co., Cambridge, England). The cellular morphology was recorded through QWin software and images were processed using Adobe Photoshop 5.5 (Adobe Systems, Inc., Mountain View,
CA, USA) software. For scanning electron microscopy KalsomeTM10 treated and untreated cells were first quick-fixed in 2.5% glutaraldehyde and then post-fixed with 1% OsO₄. These processed cells were gradually dehydrated and air-dried. They were finally sputter-coated with gold palladium and examined in a JEOL JSM-5200 electron microscope using an accelerating voltage of 20 kV.

**Evaluation of Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) binding of cells through flow cytometry**

Binding of Annexin V-FITC/PI to cells was assessed using FITC Annexin V Apoptosis Detection Kit II (BD Pharmingen™, New Jersey, USA) according to the manufacturer’s instructions. Briefly, 100 μl of promastigotes (1x10⁷/ml) incubated with varying concentrations of KalsomeTM10, Ambisome and amphotericin B for different time periods were harvested and washed twice with cold PBS. Then they were resuspended in 100 μl binding buffer and transferred to a 5 ml culture tube. 5 μl of FITC Annexin V was added and the cells were incubated for 15 min at room temperature (25˚C) in the dark. 400 μl of binding buffer was further added to each tube along with 5 μl PI. The cells were then analysed on a flow cytometer (Becton Dickinson, LSR Fortessa, New Jersey, USA) using FACS Diva software (BD Biosciences, New Jersey, USA).

**Measurement of mitochondrial membrane potential (Δψₘ) and mitochondrial integrity**

Mitochondrial membrane potential (Δψₘ) was measured using the BD™ MitoScreen flow cytometry mitochondrial membrane potential detection kit, according to the manufacturer’s instructions. Briefly, 100μl of KalsomeTM10-treated and non treated L. donovani promastigotes (1x10⁷/ml) were collected and centrifuged at 400 × g for 5 minutes at room temperature. Supernatant was then carefully removed and the cells were resuspended in 0.5 ml of freshly prepared working solution of JC-1 dye and incubated for 10–15 min at 37˚C in a CO₂ incubator. Subsequently, the stained cells were washed twice and resuspended in 0.5 ml of assay buffer for analysis by flow cytometry in Becton Dickinson, LSR Fortessa using FACS Diva software.

**Evaluation of intracellular ATP depletion**

The depletion of the intracellular ATP pool in KalsomeTM10 treated and untreated cells was measured using the ATP determination Kit (Molecular Probes) according to the manufacturer’s instructions. Briefly, the cells were washed and then resuspended in PBS. To this cell suspension, 9 volumes of boiling 100 mM Tris, 4 mM EDTA pH 7.75 was added and further incubated for 2 min at 100˚C. Cells were then centrifuged and the supernatants transferred to a fresh tube on ice until measurement. The sample lysate was then mixed with the reaction buffer provided in the kit and the concentration of ATP was determined using ATP standard curve generated from the readings on Synergy H1 Hybrid reader (BioTek).

**Determination of intracellular reactive oxygen species (ROS) generation**

Intracellular H₂O₂ levels in treated and untreated cells were measured using the ROS-Glo assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The KalsomeTM10 treated and untreated cells were added to an opaque white 96 well plate in RPMI media. The H₂O₂ substrate solution was then added, making the final volume to 100 μl. The plate was then incubated at 37˚C in a 5% CO₂ incubator for 60 min. 100 μl of the ROS-Glo
detection solution was then added to each well. After additional 20 min incubation at room temperature, bioluminescent readings were obtained using a Synergy H1 Hybrid reader (Bio-Tek). Mitochondrial superoxide in KalsomeTM10 treated and untreated cells was measured using MitoSOX™ red and analysed on a flow cytometer (Becton Dickinson, LSR Fortessa) with FACS Diva software.

**Determination of intracellular glutathione (GSH) content and lipid peroxidation products**

Intracellular GSH content in treated and untreated cells was measured using the Glutathione Fluorometric Assay Kit (Biovision, USA) according to the manufacturer’s instructions. Briefly, the sample lysate was mixed with the reaction buffer provided in the kit and the concentration of GSH was calculated from the GSH standard curve generated using the readings on Synergy H1 Hybrid reader (BioTek). For the estimation of lipid peroxidation products, the treated and untreated cells were washed twice with PBS and suspended in 1 ml of 15% sodium dodecyl sulfate (SDS)-PBS solution. The fluorescence intensities of the total fluorescent lipid peroxidation products was then obtained [13] through readings on Synergy H1 Hybrid reader (BioTek) with excitation at 360 nm and emission at 430 nm.

**Evaluation of in vivo caspase-like activity**

In vivo caspase-like activity in KalsomeTM10, Ambisome and amphotericin B treated and untreated cells were determined using Intracellular Caspase Detection ApoStat kit (R&D Systems, Inc., Minneapolis, USA) according to the manufacturer’s instructions. Briefly, cells were stained directly during the last 30 minutes of the apoptosis induction period. For this, 1 μl of ApoStat per 100 μl of culture volume was added. The staining was performed at 37˚C. Cells were then harvested into 1 ml tubes, centrifuged at 500 x g for 5 minutes and washed once with 1 ml of PBS to remove unbound reagent. The cells were then resuspended in 500 μl of PBS for analysis on a flow cytometer (Becton Dickinson, LSR Fortessa) with FACS Diva software.

**Terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL) assay**

TUNEL assay was performed according to the manufacturer’s instructions (ApoAlert™ DNA Fragmentation Assay Kit, Takara Bio, Inc., USA). Briefly, 500 μl of KalsomeTM10 treated and untreated promastigotes was harvested by centrifugation and washed twice with 1 ml of PBS. The cells were then resuspended in 0.5 ml of PBS and fixed by adding 5 ml of fresh, prechilled 1% formaldehyde/PBS and incubated at 4˚C for 20 min (step repeated two times). Resuspended cells in 0.5 ml of PBS were then permeabilized by adding 5 ml of 70% ice-cold ethanol and incubated at –20˚C for at least 4 h. The cells were washed twice in PBS and then transferred to an amber 1.5-ml microcentrifuge tube (to protect samples from light). The cells were then resuspended in 80 μl of equilibration buffer and incubated at room temperature for 5 min. The cells were washed with PBS and resuspended in 50 μl of TdT incubation buffer and incubated at 37˚C in a water bath for 60 min, protected from direct light. Then 1 ml of 20 mM EDTA was added to terminate the reaction, and mixed by gentle vortexing. The cells were pelleted down by centrifugation and resuspended in 1 ml of 0.1% Triton X-100/BSA/PBS. The cells were then resuspended gently in 0.5 ml of PI/RNase/ PBS to stain with PI following incubation at room temperature in the dark for 15–30 min. They were analyzed on a flow cytometer, Becton Dickson Canto II with BD FACS Scan Software (San Diego, CA, USA).
DNA laddering experiment

Fragmentation of DNA into oligonucleosomal bands, as a function of apoptotic cell death, was studied by DNA laddering assay as described before [14]. Apoptotic DNAs from 1 ml of KalsomeTM10 treated and untreated L. donovani promastigotes (1x10^7/ml) were isolated using Suicide Track™ DNA Ladder Isolation Kit (Calbiochem, Germany). Briefly, the treated and untreated cells were suspended in 500 μl of extraction buffer which separates apoptotic DNA from high molecular weight DNA. The cells were then incubated on ice for 30 min and centrifuged at 15000 x g for 5 min. Supernatants carefully removed and transferred to a clean tube. RNA in the supernatant was then degraded using solution 2 of the kit. Subsequently, DNA from the cell lysate was isolated using solution 3 and incubation at 50°C for 1 h. The DNA pellet obtained after centrifugation was washed with 70% ethanol followed by 100% ethanol. It was further air dried and resuspended in buffer (10 mM Tris pH 7.5, 1 mM EDTA). DNA aliquots were electrophoresed on 1.5% agarose gel containing ethidium bromide (0.5μg/ml), using Tris—acetate—EDTA (pH 8.0) running buffer, and then observed and photographed under UV illumination in a BioRad gel documentation system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Cell cycle analysis

Cell cycle analysis of KalsomeTM10 treated and untreated L. donovani promastigotes was done using flow cytometry. After treatment of promastigotes with varying concentrations of KalsomeTM10 for different time periods, the cells were harvested and washed thrice with PBS and fixed in 50% ethanol (diluted in PBS) for 4 h. The fixed cells were then washed thoroughly, treated with 100 μg/ml RNase A and suspended in 1ml of staining solution. After 1 h, the cells were stained with 40 μg/ml PI for 20 min at room temperature. The percentage of cells in G1, S and G2/M phases of the cell cycle were determined in Becton Dickson Canto II flow cytometer and with BD FACS Scan Software.

Isolation of peritoneal macrophages and in vitro evaluation against intracellular amastigotes

BALB/c mice, 6–8 weeks old were used for the experiments. Mouse peritoneal macrophages were collected by infusing the peritoneal cavity with ice-cold sterile RPMI supplemented with 3% FCS. For in vitro infection studies 5 x 10^6 peritoneal macrophages were cultured on cover slips and incubated overnight. Next day unattached cells were washed off and then infected with parasites at 1:10 ratio. After 3 h of incubation the unbound parasites were removed by washing thrice with PBS. The infected cells were then treated with increasing concentrations of KalsomeTM10, Ambisome and amphotericin B for 1 h after which the cells were washed with PBS and then incubated in fresh medium for 72 h post infection. The coverslips were then washed twice with PBS and air dried. After methanol fixation the coverslips were stained with giemsa and the infected cells were counted on a light microscope using oil emersion lenses and the images were recorded and processed using Adobe Photoshop 5.5 software.

Detection of DNA fragmentation in intracellular amastigotes

DNA fragmentation in intracellular amastigotes was analysed by fluorescence microscopy using the In Situ Apotosis Detection Kit (Trevizen, USA). Mouse peritoneal macrophages (1 x 10^6) were plated in 8-chamber slides (SPL, Korea) and incubated at 37°C in 5% CO2 overnight. Next day unattached cells were washed off and then infected with parasites at 1:20 ratio. After 3 h of incubation the unbound parasites were removed by washing thrice with PBS. The
infected cells were then incubated for further 24 h post infection and then treated with Kal-
someTM10, Ambisome and amphotericin B for 1h after which the cells were washed with PBS
and then incubated in fresh medium for 72 h post infection. The coverslips were then washed
twice with PBS and fixed with 3.7% formaldehyde. The slides were then stained using the In
Situ Apoptosis Detection Kit and examined using fluorescence microscopy.

Statistical calculations
All data comparisons were tested for significance using two tailed Student’s t-test using Graph-
Pad software; P values <0.05 were considered significant.

Results
Size and size distribution of KalsomeTM10 and Ambisome
Size distribution of liposomal particles is critical to their function [15], therefore, to assess the
mean size and size distribution of KalsomeTM10 and Ambisome, NTA measurement with
NanoSight LM20 [16] was performed. We found that the mean hydrodynamic diameter of
KalsomeTM10 and Ambisome was 119.5± 14.85 nm and 128.0± 1.414, respectively. Moreover,
SD of KalsomeTM10 and Ambisome was found to be 56.50± 14.85 and 53.00± 8.485, respec-
tively, indicating that both these liposomal formulations have similar size distribution pattern
in addition to their mean size in the range of nm. Numbers representing average
values ± standard deviation (n = 2 measurements) (S1 Fig).

KalsomeTM10 induces killing of L. donovani promastigotes but not
macrophages in a time- and concentration-dependent manner
We then investigated the time and dose dependent effect of KalsomeTM10 on promastigotes
and macrophages. Treatment of promastigotes for a particular time point with increasing
doses of KalsomeTM10 ranging from 0.5–10.0 μg/ml showed a gradual reduction in the cell
viability (Fig 1a). Moreover, when the incubation time was increased from 2 to 8 h, drug dose
needed for effective killing of the parasite also decreased (Fig 1b). It was found that more than
50% of cells lost viability when treated with 7.5 μg/ml of drug at 2h, which was comparable to
those treated with 5.0μg/ml and 2.5 μg/ml of the drug at 4h and 6h, respectively. This suggests
that KalsomeTM10 treatment exhibits a time- and concentration- dependent killing of L.
donovani promastigotes. To assess the effect of KalsomeTM10 on mammalian cells, we treated
mouse peritoneal macrophages with increasing doses of the drug for 48h and 72h, and mea-
sured cell viability. Interestingly, we found no significant killing of macrophages at any of
the drug doses used (Fig 1c). Taken together, these results suggest that KalsomeTM10 is efficient
in killing L. donovani promastigotes with no toxic effect on mammalian cells.

Leishmanicidal effect of KalsomeTM10 in infected macrophages is dose
dependent
Macrophages are the primary host cells, in which Leishmania parasites reside and multiply in
the form of amastigotes [17]. Therefore, to assess the efficacy of KalsomeTM10, we treated L.
donovani infected macrophages with increasing doses of the drug and determined the infectiv-
ity index (no. of amastigotes/100 macrophages) after 72 h of incubation. We found that Kal-
someTM10 exhibits a significant killing of intracellular parasites as revealed by decreasing
number of amastigotes in infected macrophages, which was totally cleared of at the highest
dose used (Fig 2a). The same was represented as Giemsa stained macrophages where progres-
se reduction in the no. of intracellular parasites proportionate to the increasing dose of
Fig 1. Effect of KalsomeTM10 on the viability of *L. donovani* promastigotes and macrophages. (a) Promastigotes were treated with increasing concentrations of KalsomeTM10 at different time points (2, 4, 6 and 8 h) and the percentage cell viability was estimated. (b) The ED\textsubscript{50} and ED\textsubscript{90} were determined for each time point. (c) Percent cell viability of murine peritoneal macrophages treated with increasing drug concentrations for 24h and 48h was determined. Results are presented as means±SD; n = 3.

doi:10.1371/journal.pone.0171306.g001

![Graph showing the effect of KalsomeTM10 on cell viability.](image)

| Time (h) | 2h   | 4h   | 6h   | 8h   |
|----------|------|------|------|------|
| ED\textsubscript{50} (µg/ml) | 4.56±0.3818 | 4.10±0.2758 | 3.91±0.1344 | 3.76±0.0636 |
| ED\textsubscript{90} (µg/ml) | 8.21±0.6930 | 7.39±0.5020 | 7.04±0.2333 | 6.78±0.1202 |

Fig 2. In-vitro leishmanicidal effect of KalsomeTM10 on peritoneal macrophages infected with promastigotes of *L. donovani*. Macrophages, infected with promastigotes, were treated with different concentrations of KalsomeTM10 for 72 h post infection. The infected macrophages on coverslips were giemsa stained and counted on a light microscope (a). Number of amastigotes per 100 macrophages was represented as bar graph. Results are presented as means ± SD; n = 3. Infected macrophages untreated (b i) and treated with 10 ng/ml (b ii), 50 ng/ml (b iii), 100 ng/ml (b iv), 500 ng/ml (b v) and 1000 ng/ml (b vi) of KalsomeTM10, were giemsa stained and imaged on a light microscope. Pictorial representation of three independent experiments is depicted.

doi:10.1371/journal.pone.0171306.g002

![Image showing the effect of KalsomeTM10 on infected macrophages.](image)
KalsomeTM10 treatment was observed (Fig 2b). The phase contrast micrographs of infected macrophages treated with higher concentrations of KalsomeTM10 has also been shown depicting no much difference in the morphology of the infected macrophages compared to the drug treated infected macrophages (S4 Fig) These results suggest that KalsomeTM10 has potent anti-leishmanial activity against intracellular infection model of VL.

KalsomeTM10 induces efficient killing of L. donovani promastigotes and intracellular amastigotes compared to Ambisome and amphotericin B

We then compared the in vitro activity of KalsomeTM10 with Ambisome and amphotericin B, taken as control drugs, against promastigotes and intracellular amastigotes in peritoneal macrophages. Promastigotes and intracellular amastigotes were treated with different doses of these drugs for 4h and 72 h respectively, and ED$_{50}$ and ED$_{90}$ was determined. KalsomeTM10 showed 50 percent (4.73±0.1282 μg/ml, 0.364±0.0140) and 90 percent (7.87±0.2310 μg/ml, 0.6670±0.043) killing of promastigotes and intracellular amastigotes respectively, at a dose of almost half than that required by Ambisome with ED$_{50}$ (7.548±0.1189, 0.862±0.0225) and ED$_{90}$ (13.59±0.2140, 1.552±0.0404), respectively. Although amphotericin B showed 50 percent (0.257±0.0142 μg/ml) and 90 percent (0.437±0.0254) killing of promastigote forms at very low dose, it requires higher concentrations, ED$_{50}$ (2.00±0.0230) and ED$_{90}$ (3.609±0.024), respectively, to exhibit intracellular killing of the parasites compared to KalsomeTM10 with ED$_{50}$ (0.364±0.0140) and ED$_{90}$ (0.6670±0.043), respectively. Moreover, amphotericin B exhibits toxic effect towards macrophages with increasing doses compared to KalsomeTM10 and Ambisome (Table 1).

Determination of cellular morphology in L. donovani promastigotes

We next investigated the mechanism of cell death in KalsomeTM10 treated promastigotes. Morphological changes are one of the key hallmarks that distinguishes apoptotic and necrotic mode of cell death [18]. So, we initially studied the morphological changes in promastigotes treated with different concentrations of KalsomeTM10 at 4 h. Phase contrast micrographs depicted a significant reduction in size and shape of promastigotes along with substantial loss of flagella, at 1.0 μg/ml of drug treatment compared to the untreated controls (Fig 3a and 3b). Promastigotes treated with 2.5 μg/ml and 5.0 μg/ml of the drug, displayed complete rounding in shape along with cytoplasmic condensation and shrinkage (Fig 3c and 3d). In addition, SEM analysis also showed a decrease in cell size, loss of flagella, acquisition of ovoid and irregular shape and severe distortion in cell membrane in KalsomeTM10 treated parasites

| Tables 1. KalsomeTM10, Ambisome and amphotericin B differentially affect the viability of L. donovani parasites and the mammalian macrophages.

| Drugs         | Promastigotes | Intracellular amastigotes | Toxicity % macrophage survival at 10 μg/ml (±SD) |
|---------------|---------------|---------------------------|--------------------------------------------------|
|               | ED$_{50}$ (μg/ml) | ED$_{90}$ (μg/ml) | ED$_{50}$ (μg/ml) | ED$_{90}$ (μg/ml) |                |
| KalsomeTM10   | 4.37±0.1282  | 7.87±0.2310  | 0.364±0.0140  | 0.667±0.043  | > 100          |
| Ambisome      | 7.548±0.1189 | 13.59±0.2140 | 0.862±0.0225  | 1.552±0.0404 | > 100          |
| Amphotericin B| 0.257±0.0142 | 0.437±0.0254 | 2.00±0.0230  | 3.609±0.024  | 74.37±3.913   |

Promastigotes were treated with increasing concentrations of these drugs at 4 h and the percentage cell viability was estimated. The ED$_{50}$ and ED$_{90}$ were determined. Infected macrophages were treated with increasing concentrations of these drugs at 48 h and the no. of parasites per 100 macrophages was determined. The ED$_{50}$ and ED$_{90}$ were determined. Percent cell viability of murine peritoneal macrophages treated with increasing drug concentrations for 24h was determined. Results are presented as means±SD; n = 3.

doi:10.1371/journal.pone.0171306.t001
compared to the untreated control, which possessed elongated morphology with anterior flagella and smooth membrane (Fig 4). These observations suggest that KalsomeTM10 induces significant apoptotic-like morphological changes in promastigotes of *L. donovani*.

KalsomeTM10 induces externalisation of membrane-associated phosphatidylserine (PS) in promastigotes of *L. donovani*

In the early phase of cellular apoptosis plasma membrane loses asymmetry. This leads to the translocation of phosphatidylserine (PS) from inner to the outer leaflet [19]. Annexin V is a protein which binds to PS. Conversely, PI is a non-permeable dye which selectively enters necrotic cells where it binds to nucleic acids [20]. Therefore, Annexin V-FITC and PI were simultaneously used to assess whether KalsomeTM10 exhibits apoptotic or necrotic mode of cell death in *L. donovani* promastigotes. For this, flow cytometry was employed which can distinguish cells undergoing early apoptosis [annexin V (+), PI (-)], late apoptosis [annexin V (+), PI (+)], necrosis [annexin V (-), PI (+)] and those that still remained alive [annexin V(-), PI(-)]. Treatment of promastigotes with KalsomeTM10 at 1 h showed a dose-dependent increase in the percentage of early apoptotic cells [annexin V (+), PI (-)] from 20.0% (2.5 μg/ml) to 29.7% (5.0 μg/ml) compared to the untreated control. However, at 2 h treatment, although early apoptotic cells decreased from 28.7% (2.5 μg/ml) to 20.0% (5.0 μg/ml), a simultaneous increase in the percentage of late apoptotic cells [annexin V (+), PI (+)] from 37.8 (2.5 μg/ml) to 45.5% (5.0 μg/ml) were observed, which indicated that with increase in drug exposure time, cells undergo into the late phase of apoptosis. Interestingly, no
significant necrotic cells [annexin V (-), PI (+)] were observed (Fig 5). As a control, when promastigotes were treated with Ambisome (7.5 μg/ml) and amphotericin B (0.25 μg/ml) at 1h it showed 8.7% and 28.3% of early apoptotic cells [annexin V (+), PI (-)], respectively compared to the untreated control (S2 Fig). These results strongly indicate that...
KalsomeTM10 exhibits an apoptotic-like mode of cell death by inducing externalisation of membrane PS in promastigotes of *L. donovani*.

**KalsomeTM10 induces mitochondrial dysfunction by depolarizing mitochondrial membrane potential (Δψ<sub>m</sub>) and disrupting mitochondrial integrity with a major impact on depletion of cellular ATP pool in *Leishmania* parasites**

Altered mitochondrial function during apoptosis is linked to a change in the mitochondrial membrane potential [21]. JC-1, a cationic, lipophilic and Δψ<sub>m</sub> sensitive dye, is used to measure such change. In intact mitochondria, JC1, in the form of molecular aggregates, emits red fluorescence, but with depolarisation of mitochondrial membrane potential, it comes out in the cytoplasm, in monomeric form, and emits green fluorescence. This results in the decrease in red/green fluorescence intensity ratio [22]. Thus, to verify the effect of KalsomeTM10 on mitochondrial dysfunction, we monitored mitochondrial membrane potential through flow cytometry. We found that KalsomeTM10 exhibits a dose-dependent decrease in the red/green fluorescence intensity ratio compared to the untreated control at 1h of treatment. This was evident from the percentage of cells in the red region and the green region (36.7% and 59.8% for untreated control, 7.7% and 80.7% when treated with 2.5μg/ml KalsomeTM10 and 3.0% and 87.3% when treated with 5.0 μg/ml of KalsomeTM10, respectively) (Fig 6ai–6aiii). In order to further confirm the involvement of mitochondrial apoptotic pathway in KalsomeTM10 treated promastigotes, we assessed the physical integrity of mitochondria using MitoTracker Deep Red (a stain which enters only actively respiring mitochondria in live cells). Flow cytometry analyses showed that the percentage of Mitotracker positive cells decreased in a time-dependent manner, when promastigotes were treated with 2.5μg/ml of KalsomeTM10 (Fig 6bi–6biii). This could be observed in the form of Mean fluorescence intensity (MFI), whose value fell drastically in the treated cells compared to the untreated control (Fig 6biv). Based on these results, we sought to determine, whether KalsomeTM10 affects the intracellular pool of ATP, as mitochondria are the major contributors to ATP generation, and any disruption in the mitochondrial structure and function would directly affect the intracellular ATP levels [23]. To address this, we treated promastigotes with different doses of KalsomeTM10 at 4 h and measured ATP content using a bioluminscence kit (Invitrogen). Our results showed that KalsomeTM10 induces a dose-dependent depletion in the total intracellular ATP content, which was to the extent of 27%, 60%, 72% and 80% at 1, 2.5, 5.0 and 7.5 μg/ml of KalsomeTM10 treatment respectively, compared to the untreated control (Fig 6c). Collectively, these results suggest that KalsomeTM10 causes a major mitochondrial dysfunction by inducing depolarisation of mitochondrial membrane potential, loss of mitochondrial integrity and depletion of cellular ATP pool in promastigotes of *L. donovani*.

**KalsomeTM10 leads to the generation of intracellular reactive oxygen species (ROS) and lipid peroxidation products in promastigotes of *L. donovani***

Oxidoredox homeostasis is essential for cellular survival. During apoptosis altered mitochondrial function results in overproduction of ROS that leads to an oxidative stress and cellular damage [24]. To investigate whether KalsomeTM10 induces ROS generation in leishmanial cells, we measured cellular H<sub>2</sub>O<sub>2</sub> using a bioluminescence kit (promega). We found that KalsomeTM10 facilitates a dose- (2.5 and 5.0 μg/ml) and time- (0.5 to 2 h) dependent increase in H<sub>2</sub>O<sub>2</sub> production which however, diminished progressively, when the treatment was carried out in presence of increasing concentrations of the ROS scavenger N-acetyl-L-cysteine (NAC)
We also studied the effect of KalsomeTM10 on mitochondrial superoxide (O$_2^-$) production through flow cytometry. Again, our results showed a dose- and time-dependent increase in mitochondria O$_2^-$ production in leishmanial cells with no such production in untreated control (Fig 7b and 7c). With these results, we sought to verify, whether KalsomeTM10 treatment has any effect on the cellular pool of glutathione (GSH), since redox status in cells is under the tight control of GSH, a potent antioxidant molecule [25]. We measured GSH content in KalsomeTM10 (2.5 μg/ml) treated promastigotes using a fluorometric assay kit (Biovision) and found that there was a marked depletion in GSH pool in drug treated parasites compared to the untreated controls (Fig 7d).
Lipid peroxidation, a process in which oxidants such as free radicals target polyunsaturated fatty acids resulting in lipid peroxyl radicals and hydroperoxides generation, is detrimental to cells leading to their death either through apoptotic or necrotic mode [26]. Thus, to assess whether KalsomeTM10 induces generation of lipid peroxidation products, we treated promastigotes at 2 h with varying doses of the drug and measured lipid peroxidation products fluorometrically. Our results showed that KalsomeTM10 induces a dose-dependent increase in these products (Fig 8a). To further confirm that KalsomeTM10 does so by generating ROS, we treated promastigotes with KalsomeTM10 in the presence of NAC. The results showed diminished production of lipid peroxidation products in the presence of NAC, indicating that KalsomeTM10 exhibits potent ROS generation in promastigotes that leads to the production of these products (Fig 8b). Altogether, these observations suggest that KalsomeTM10 mediated mitochondrial dysfunction results in over production of free radicals with concomitant depletion of intracellular GHS content and increased generation of lipid peroxidation products, which triggers apoptotic-like mode of cell death in promastigotes.

**Induction of in vivo caspase-like activity in L. donovani by KalsomeTM10**

Caspases are one of the key molecules which orchestrate the process of apoptosis [27]. Thus to determine, if caspases really play any role in KalsomeTM10 mediated cell death in promastigotes, we used Apostat (a cell permeable caspase specific substrate with fluorescent tag; from **Fig 7. ROS and mitochondrial super-oxide production, and depletion of GSH pool in KalsomeTM10 treated promastigotes.** Promastigotes incubated at different time points with KalsomeTM10 at 2.5 μg/ml (a i) and 5.0 μg/ml (a ii), with or without NAC (1 mM and 10 mM). Cellular ROS was measured by bioluminescence assay. Results are presented as means + SD; n = 3. Promastigotes, untreated (b i and ii) and treated with 2.5 μg/ml of KalsomeTM10 for 30 min (b iii) and 1 h (b iv), and treated with 5.0 μg/ml of KalsomeTM10 for 30 min (b v) and 1 h (b vi), were stained with mitosox, and analysed by flow cytometry. The histograms are representative of three independent experiments. (c) Bar graphs representing mean % superoxide* cells. (d) Promastigotes treated with 2.5 μg/ml of KalsomeTM10 at different time points and GSH concentration determined fluorometrically. Results are presented as means + SD; n = 3. * P<0.01, ** P<0.001.
R&D), which detects intracellular active caspase. Flow cytometric analyses showed that Kal-
someTM10 treatment induces a dose- and time- dependent increase in caspase positive cells, which was significantly reduced by the pan caspase inhibitor, z-VAD-fmk, suggesting that Kal-
someTM10 activates caspase mediated apoptotic machinery in promastigotes of *L. donovani* (Fig 9a). To further confirm the involvement of caspases, we performed cell viability assay in the presence and absence of z-VAD-fmk. Our results showed that z-VAD-fmk significantly reduced cell death in promastigotes at 1h treatment of KalsomeTM10 (2.5 μg/ml) (Fig 9b), which also reflected in the decrease in the percentage of annexin-v positive cells (Fig 9c). Treatment of promastigotes with Ambisome (7.5 μg/ml) and amphotericin B (0.25 μg/ml) at 1h also showed induction of caspase positive cells (S3 Fig). These results suggest that KalsomeTM10 mediated cell death in promstigotes of *L. donovani* is caspase dependent.

**Determination of apoptotic-like cell death by oligonucleosomal DNA fragmentation in *L. donovani* promastigotes**

The cleavage pattern of genomic DNA characterized by fragmentation into nucleosomal units is a distinctive feature of apoptotic cell death [28]. To investigate whether KalsomeTM10 exhibits DNA fragmentation in *L. donovani* promastigotes, we performed TUNEL staining that detects fragmented DNAs by labelling their free ends with dUTP. We found that Kal-
someTM10 significantly increased TUNEL positive cells in a dose-dependent manner com-
pared to the untreated control cells (Fig 10a). To further substantiate this observation, we also performed DNA laddering assay, by employing agarose gel electrophoresis. The results showed that there was marked fragmentation in genomic DNA into oligonucleosome-sized fragments (in multiples of 200 bp) when promastigotes were treated with 1.0 μg/ml (lane 3), 2.5 μg/ml (lane 4), and 5.0 μg/ml (lane 5) of KalsomeTM10. In contrast, untreated cells (lane 2) did not show any DNA fragmentation (Fig 10b). Moreover, it is evident from Fig 10b that DNA lad-
dering initiated at the lowest drug dose and with further increase in the dose, there was a marked decrease in the size of the intact DNA with a corresponding increase in the DNA lad-
dering when compared to the untreated controls. Overall, these results suggest that
KalsomeTM10 causes genomic DNA fragmentation, which might contribute to the induction of apoptotic-like cell death in *L. donovani* promastigotes.

KalsomeTM10 induces cell cycle arrest in *L. donovani* promastigotes

Degradation of genomic DNA has profound effects on the replication of cells [29]. To verify whether KalsomeTM10 affects promastigote's replication, we treated parasites with different doses of the drug at varying time points, and analysed cell cycle progression through flow
The results indicated that KalsomeTM10 induces a dose- and time-dependent arrest of leishmanial cells, since the percentage of cells in the sub-G0 phase of the cell cycle increased when compared to the untreated control (Fig 11a and 11b).

**KalsomeTM10 induces apoptotic DNA fragmentation in intracellular amastigotes of *L. donovani***

To determine the mechanism of killing of intracellular amastigotes, peritoneal macrophages were infected with stationary phase promastigotes of *L. donovani*. After 24h of incubation, infected macrophages were treated with KalsomeTM10 and control drugs Ambisome and amphotericin B for 48h. TUNEL assay show that compared to untreated infected macrophages (Fig 12a) KalsomeTM10 treatment induces DNA degradation into apoptotic fragments as revealed by prominent green signal in the amastigotes without affecting macrophage DNA (Fig 12b). Ambisome (Fig 12c) and amphotericin B (Fig 12d) also induced DNA fragmentation but with low efficacy compared to KalsomeTM10 as revealed by the moderate green signal intensity.

**KalsomeTM10 mediated killing of intracellular amastigotes is ROS and nitric oxide dependent**

ROS and nitric oxide are potent anti-leishmanial molecules [30,31]. Therefore, to verify if KalsomeTM10 induces generation of these molecules as a probable mechanism of killing intracellular amastigotes, peritoneal macrophages were infected with promastigotes of *L. donovani*. After 24 h of incubation, infected macrophages were treated with KalsomeTM10 in absence and presence of the ROS scavangers (NAC, PEG-Cat and PEG-SOD) and nitric oxide synthesis inhibitor (L-NMMA) for 48 h and the infectivity index (no. of amastigotes/100 macrophages) was determined. We found that KalsomeTM10 mediated killing of intracellular parasites was significantly inhibited in the presence of the above mentioned ROS scavengers.
and nitric oxide synthesis inhibitor revealing that KalsomeTM10 employs these antimicrobial molecules to kill the parasites (Fig 13).

Endocytosis play important role in KalsomeTM10 mediated but not amphotericin B mediated killing of intracellular amastigotes

Endocytosis of liposomal formulations to cells is crucial to their function [32,33]. Therefore, to evaluate if endocytosis is necessary for KalsomeTM10 and amphotericin B mediated anti-leishmanial effects, peritoneal macrophages were infected with promastigotes of *L. donovani*. After 24 h of incubation, infected macrophages were pretreated with cytochalasin D for 1h and then treated with KalsomeTM10 and amphotericin B for 1h. After washing the cells, further incubation for 48 h was carried out and the infectivity index (no. of amastigotes/100 macrophages) was determined. We found that KalsomeTM10 mediated killing of intracellular parasites was significantly inhibited in the presence of the cytochalasin D but no such inhibition was observed in amphotericin B treated macrophages, indicating that endocytosis has crucial role in KalsomeTM10 mediated anti-leishmanial effect (Fig 14a).

Cholesterol depletion on host macrophage diminished KalsomeTM10 and amphotericin B mediated killing of intracellular amastigotes

Amphotericin B binds to membrane cholesterol [32], therefore, to determine if cholesterol depletion of macrophage affects the leishmanicidal function of kalsomeTM10 and amphotericin B, peritoneal macrophages were infected with promastigotes of *L. donovani*. After 24 h of
incubation, infected macrophages were pretreated with MβCD for 40 mins and then treated with KalsomeTM10 and amphotericin B for 1h. After washing the cells, further incubation for 48 h was carried out and the infectivity index (no. of amastigotes/100 macrophages) was determined. We found that not only amphotericin B but also KalsomeTM10 mediated killing of...
intracellular parasites was significantly inhibited in cholesterol depleted macrophages, indicating that membrane cholesterol plays crucial role in KalsomeTM10 and amphotericin B mediated anti-leishmanial effect (Fig 14b).

Discussion

The in vivo anti-leishmanial efficacy of KalsomeTM10 that we reported in our previous work, prompted us to investigate the relevant cell death mechanism, by which KalsomeTM10 induces killing of the parasites without affecting the host. To our knowledge no such study using a liposomal formulation of amphotericin B has been reported that show induction of apoptotic-like cell death in both promastigotes as well as intracellular amastigotes of *L. donovani*. Though, induction of programmed cell death in promastigotes of *L. donovani* in response to amphotericin B treatment only, has been described [34], but again, its mechanism of killing on the intracellular amastigotes is lacking. Even Ambisome, (another liposomal amphotericin B), which we took as a control, and that was not previously shown, was found to induce similar kind of apoptotic changes in both promastigotes as well as intracellular amastigotes as induced by KalsomeTM10. However, for attaining similar kind of anti-leishmanial response, concentration of Ambisome required was almost double than that of KalsomeTM10. This indicates to the potential of KalsomeTM10 over Ambisome, since KalsomeTM10 can meet therapeutic dose of amphotericin B without increasing the amount of lipids (used for the delivery of the free drug), thereby, lowering the risk of lipid associated side effects on the host [35,36].
The mechanistic aspect of cell death in KalsomeTM10 treated promastigotes depicted apoptotic like morphological alterations similar to several anti-leishmanials [37,38] with reduction in the body length, rounding of cells, loss of flagella and cell shrinkage etc. Further, study on PS externalisation, an early event of apoptosis [39,40] showed that KalsomeTM10 can exhibit this in a dose- and time-dependent manner. Interestingly, no PI positive cells were observed indicative of an apoptotic-like mode of cell death. Ambisome treatment also showed PS exposure. However, the efficacy of Ambisome was significantly lower compared to KalsomeTM10 and amphotericin B. This was evidenced by the percentage of PS positive cells (8.7%) observed after Ambisome treatment at 7.5 μg/ml, which was ~3 fold less than the percentage of PS positive cells after kalsomeTM10 (28.7%) and amphotericin B (28.3%) treatment at 5 μg/ml and 0.25 μg/ml, respectively. One plausible mechanism for this could be the delayed accessibility of free amphotericin B to the Leishmania membrane [32], as amphotericin B alone at a very low dose of 0.25 μg/ml manifested comparable amount of PS positive cells, to that shown by 5 μg/ml amphotericin B when encapsulated in KalsomeTM10. Remarkable differences between the action of Ambisome and KalsomeTM10 may be explained by the lamelarity as well as cholesterol content of these two liposomal formulations. Ambisome is a unilamellar bilayer liposome containing cholesterol, where amphotericin B is intercalated within the membrane bilayer [11]. However, KalsomeTM10 is a multilamellar liposome [8], where in addition to the higher amount of intercalated amphotericin B due to ergosterol, a significant amount of soluble amphotericin B can be present in the aqueous compartment between the lipid bilayers making the possibility of membrane accessible amphotericin B significantly higher [32].

Fig 14. Effect of cytochalasin D and MβCD on in-vitro leishmanicidal effect of KalsomeTM10 and amphotericin B on intracellular amastigotes. Macrophages, infected with promastigotes, for 24 h were pretreated with cytochalasin D (25 mM) (a) and MβCD (20 mM) (b) for 30 mins and then treated with KalsomeTM10 (0.5 μg/ml) and amphotericin B (3 μg/ml) for 1h in cytochalasin D treated macrophage and for 30 mins in MβCD treated macrophages. After washing, incubation for 48 h post drug treatment in the presence of these scavengers and inhibitor was carried out and then the infected macrophages were giemsa stained and counted on a light microscope to determine infectivity index (Number of amastigotes per 100 macrophages) that was represented as bar graph. Results are presented as means ± SD; n = 2.

***P<0.0001.
doi:10.1371/journal.pone.0171306.g014
results showing varying degree of PS exposure on promastigotes induced by KalsomeTM10, Ambisome and Amphotericin B treatment, we cannot exclude the presence of other phospholipids including phosphatidylglycerol and phosphatidyl inositol-4, 5 bisphosphate. This is because Annexin V can bind to these lipids also [41]. Presence of PS on the membrane of L. donovani is still a matter of debate. Though Weingartner showed absence of PS [42], Imbert et al. showed that in addition to other phospholipids PS is also present in the membrane of L. donovani promastigotes [43]. Interestingly, the study carried out by Banerjee et al. showed that PC-SA liposome having high affinity towards PS (confirmed by incubating with PS and other phospholipid liposomes) failed to significantly kill promastigotes preincubated with annexin V [44]. This indirectly shows that in comparison to other phospholipids, PS is in fact present in significant amount on the surface of promastigote where annexin V majorly binds in addition to other lipid moieties. Presence of PS in promastigotes of L. major was depicted through the use of annexin V, PS-specific antibody and protein S [45]. Thus, our results using annexin V binding assay suggests that treatment of promastigotes with KalsomeTM10, Ambisome and amphotericin B, lead to higher exposure of the annexin V binding phospholipids (majorly PS) on the surface of the parasites thus causing apoptotic-like cell death in these parasites. Similar to this, recently, many studies have shown PS exposure in dying parasites through annexin V binding assay upon treatment with different anti-leishmanials [46–48].

Mitochondria play crucial role in cell survival and death [49]. Since Leishmania possess a single, large mitochondrion that responds to majority of their (ATP) energy requirements, it represents a potential drug target [50]. We showed that KalsomeTM10 can induce a remarkable decrease in mitochondrial membrane potential as well as disruption in mitochondrial physical and structural integrity. Permeabilisation of mitochondrial outer membrane is critical to the mitochondrial signaling leading to cell death [24], and since lipid vehicles bear fusogenic property with the hydrophobic membranes [15], hence forth, it can be possible that the mitochondrial outer membrane would be highly sensitive to KalsomeTM10. This can be reflected by the drug exposure time that within 1 h of KalsomeTM10 treatment, a drastic fall in the red fluorescence (JC1 aggregates), indicating to the loss of mitochondrial membrane potential was observed [51]. But how KalsomeTM10 is internalised into the promastigotes is still not known which requires additional study. Further, the observation that KalsomeTM10 treatment exhibited ATP depletion could be the result of the disruption in the mitochondrial transmembrane potential (the electrochemical gradient that drives ATP synthesis) [18]. Altogether, these indicate that a loss in mitochondrial membrane potential has a significant impact on leishmanial membrane integrity [49,50,52] probably by decondensation of the kinetoplasts which are held by the inner-membrane [53], and thus hampering ATP generation. LQB 118 treated promastigotes of L. amazonensis reported similar dissipation of mitochondrial membrane potential causing cellular ATP depletion [52]. Uncoupling of mitochondrial oxidative phosphorylation is a major contributing factor to the generation of free radicals [54]. We also found that KalsomeTM10 induces a rapid increase in H$_2$O$_2$ as well as superoxide production in a dose and time dependent manner. This was further confirmed by the use of NAC (ROS quencher), which significantly reduced H$_2$O$_2$ production. These results are in accordance with Ribero et al [52], who previously demonstrated that LQB-118 induces increased generation of ROS in L. amazonensis during the early hours of treatment to trigger apoptosis. Further, evaluation of antioxidants like GSH, which protects kinetoplastids by buffering excessive ROS concentration [55,56], showed that KalsomeTM10 significantly depleted GSH content in promastigotes. In the absence of antioxidants, ROS tends to impart detrimental effects on the integrity of various lipid molecules. Lipid peroxidation products thus generated, further fuel the cell death mechanism [26]. KalsomeTM10 displayed enhanced generation of these products which diminished in the presence of NAC. Overall, these suggest that KalsomeTM10 employs
mitochondrial dependent pathway with major impact on intracellular ATP pool to exhibit apoptotic-like cell death in promastigotes of *L. donovani*.

Caspases, a specific family of cysteine proteases, play important role in executing mammalian apoptosis [57]. However, their implication in *Leishmania* apoptosis is controversial. Although some investigators demonstrated caspase-like activity others have reported caspase independent apoptotic cell death in *Leishmania* promastigotes [34,58,59]. We showed using ApoStat, a pan caspase inhibitor earlier employed to detect mammalian cell apoptosis [60,61], that KalsomeTM10 can induce a dose- and time-dependent increase in the percentage of caspase positive cells, which decreased significantly in the presence of the broad caspase inhibitor zVAD-fmk. Ambisome treatment for 1h also showed caspase induction (16.0% cells) at 7.5 μg/ml which was comparable to that induced by amphotericin B (16.4%) at 0.25 μg/ml. KalsomeTM10 however depicted higher percentage of caspase positive cells (29.5%) at 2.5 μg/ml, compared to Ambisome. Similar in vivo capase-like activity, in terms of PPL cleavage, in amphotericin B treated promastigotes has been documented [34]. Therefore, all these observations indicate that though the genome of *Leishmania* does not encode classical caspases [62], existence of proteases similar to the mammalian caspases, where this inhibitor binds, could not be excluded. Like caspases, metacaspases have been reported in protozoan parasites [63,64] but their role in *Leishmania* apoptosis is not clear. So it is unlikely to infer that ApoStat binds to these enzymes. Rather, possibility towards other putative proteases could exist, since this inhibitor can bind non-specifically to proteases like calpain, cathepsin B and cathepsin H etc. [65,66]. Nevertheless, to further confirm the involvement of caspase-like activity in KalsomeTM10 mediated killing of promastigotes, the parasites were incubated with the z-VAD-fmk during drug treatment. z-VAD-fmk significantly downregulated killing of the promastigotes as well as PS exposure. Despite this, the role of z-VAD-fmk in inhibiting other proteases like cathepsin B [66] cannot be excluded. Altogether it reveals that KalsomeTM10 induces apoptotic-like cell death in promastigotes of *L. donovani* in part via caspase dependent pathway.

Apoptotic DNA fragmentation in KalsomeTM10 treated promastigotes analysed through TUNEL assay [67] showed progressive increase in the percentage of tunel positive cells. This was further confirmed through DNA laddering assay which showed oligonuolesomal bands of fragmented DNAs. Progressive DNA laddering profile was clearly visible in cells treated with increasing drug concentrations while such patterns were not visible in the control profile. We further showed that KalsomeTM10 can induce cell cycle arrest which is likely a result of genomic DNA fragmentation that inhibits cell proliferation [68]. Flow cytometry analysis revealed that the promastigotes enter into the sub G0 stage and get arrested therein, without really entering into the mitotic (M) phase with an increase in the dose as well as time of incubation. This could be due to the activation of different nucleases which in turn facilitate oligonuolesomal fragmentation of genomic DNA, and effectively block DNA replication during the S phase of the cell cycle [68]. Taken together, DNA fragmentation and cell population arrest at sub Go/G1 phase of cell cycle, both hallmarks of classic apoptosis, confirm the apoptotic-like cell death in *L. donovani* promastigotes upon KalsomeTM10 treatment.

The various biochemical markers confirming mechanism of cell death in promastigotes led us to analyze the mechanism of cell death in intracellular amastigotes. Interestingly, we found that KalsomeTM10 induces degradation of parasite’s genomic DNA into apoptotic fragments as determined by Insitu TUNEL assay, without any effect on host cell DNA. The DNA fragmentation was more prominent compared to Ambisome and amphotericin B treated amastigotes. One previous study has shown *L. donovani* metacaspase-1 to be an effector molecule in apoptosis like cell death in the parasite [69]. We also found that KalsomeTM10 treatment of *L. donovani* infected macrophages induces metacaspase-1 expression in the intracellular parasites which was ~ 16.5 folds higher compared to the untreated control (S5 Fig)
these suggest that KalsomeTM10 also induces apoptotic-like cell death in the intracellular amastigotes. Investigation of probable mechanism for this showed that KalsomeTM10 mediated clearance of intracellular amastigotes was ROS and nitric oxide dependent, as the presence of specific scavengers and inhibitors of ROS and nitric oxide synthesis respectively, significantly inhibited KalsomeTM10 induced killing of the parasites. However, whether amastigotes-KalsomeTM10 interaction is necessary for the anti-leishmanial effect is not clear. Therefore, to further delineate whether endocytosis is indispensable in KalsomeTM10 mediated killing of the intracellular amastigotes, cytochalasin D was used. Intriguingly, KalsomeTM10 induced killing of these parasites was significantly inhibited by cytochalasin D indicating endocytosis to be important for its anti-leishmanial effect in host macrophage. However, no such inhibition upon amphotericin B treatment was observed. But how endocytosis of KalsomeTM10 is taking place is not yet clear. Moreover, any receptor present on macrophage cell surface which might be involved in uptake of this liposomal formulation after binding to some of its specific component is still not known. Previous studies on uptake of other liposome based formulations like polyethylene glycol modified liposome encapsulating hemoglobin has shown to undergo scavenger receptor mediated endocytosis in monocytes and macrophage cells [15,70]. So, it can be speculated that some surface receptor of host cell might be involved in endocytosis of KalsomeTM10. Furthermore, lack of complete inhibition in killing of parasites by cytochalasin D may be because of the pinocytosis [15] of the smaller sized particles present in KalsomeTM10 formulation. Nevertheless, this show that inhibition of endocytosis prevented entry of optimum amount of KalsomeTM10 into the cell (as most of them were washed off after 1h treatment) resulting in no significant killing of the parasites. However, binding of amphotericin B to the membrane cholesterol was strong enough to withstand its dispersal during washing. Therefore, once bound it may enter into the cells at later time point through endocytosis [33] to exhibit its anti-leishmanial effect. To further strengthen this observation, we then evaluated the effect of depletion of the macrophage membrane cholesterol (using MβCD) on the killing activity of KalsomeTM10 and amphotericin B, with the notion that it would prevent amphotericin B binding to the membrane. Surprisingly, cholesterol depletion not only inhibited amphotericin B mediated but also KalsomeTM10 mediated killing of the parasites significantly. But how this is happening is not still known. It can be speculated that due to the distortion of receptors (in cholesterol depleted membrane) [71], the liposomal components may not bind to these receptors. However, if they do bind somehow, they might not be internalized due to the aberrant recruitment of the receptors in the disrupted lipid rafts [72].

Overall this study show that inspite of showing prompt killing of Leishmania promastigotes, amphotericin B has cytotoxic effects on mammalian cells at the therapeutic dose. However, the liposomal amphotericin B showed difference in its sensitivity towards these two kinds of cells, wherein it induced apoptosis in leishmanial cells but not in the mammalian macrophages. Hence, it depicts that the delivery systems like liposomes modify the effect of amphotericin B depending on the cell types. The reason for this difference is not clear. Fusion of lipid vesicles allowing easy accessibility of free amphotericin B [32] to the Leishmania membrane may explain this observation. Nevertheless, this study shed new light into the previous perception of using lipid vesicles just as a delivery system for anti-leishmanial drugs like amphotericin B, at least when mechanism of killing of promastigotes of Leishmania is considered. Moreover, since the accessibility of these lipid based vehicles to the intracellular amastigotes cannot be excluded [73], understanding their interaction with the promastigotes form could provide new insight into the killing mechanism of the intracellular parasites. Future study on the macrophagic modulations at the mechanistic level would allow better understanding of the in vivo antimicrobial functions of KalsomeTM10. Moreover, investigating the potency of
KalsomeTM10 further on promastigotes of other *Leishmania* species like *L. amazonensis*, *L. major*, *L. braziliensis*, etc would widen the scope of this novel liposomal amphotericin B and could open up avenues for the development of similar new anti-leishmanials.

**Supporting information**

**S1 Methods. Supplementary methods.**

(DOCX)

**S1 Fig.** Size distribution from NTA measurements of the two liposomal formulations. KalsomeTM10 (A-C) and Ambisome (D-F) (left panels) with the corresponding NTA video frame (right panels) and 3D graph (size vs. intensity vs. concentration; (middle panels). (TIF)

**S2 Fig.** PS externalization in Ambisome and amphotericin B treated promastigotes. Promastigotes, untreated (a and b) and treated with Ambisome at 7.5 μg/ml (c) and amphotericin B at 0.25 μg/ml (d) for 1 h, were co stained with annexin V-FITC and PI, and analysed by flow cytometry. The dot plots are representative of two independent experiments (e) Bar graphs representing mean % PS+/PI− cells. **P<0.001, ***P<0.0001. (TIF)

**S3 Fig.** Evaluation of caspase activity in Ambisome and amphotericin B treated *L. donovani* promastigotes. Promastigotes were either left untreated (a and b) or treated with Ambisome at 7.5 μg/ml (c) and amphotericin B at 0.25 μg/ml (d) for 1 h. Caspase positive cells were analysed through flow cytometry and plotted as histograms which are representative of two independent experiments. (e) Bar graphs representing mean % caspase+ cells. ** **P<0.0001. (TIF)

**S4 Fig.** Phase contrast micrographs of peritoneal macrophages infected with promastigotes of *L. donovani*. Macrophages, infected with promastigotes, were either untreated (A) or treated with 500 ng/ml (B) and 1000 ng/ml of KalsomeTM10 for 72 h post infection. The images of these cells were captured under a light microscope. (TIF)

**S5 Fig.** Determination of metacaspase-1 gene expression in intracellular amastigotes upon KalsomeTM10 treatment. RAW 264.7 macrophages infected with promastigotes of *L. donovani* were either untreated or treated with 500 ng/ml of KalsomeTM10 for 2 h. The change in gene expression was determined through Real-time PCR using specific primers for *L. donovani* metacaspase-1 and GAPDH (used as internal control). **P<0.05. (TIF)

**Acknowledgments**

We gratefully acknowledge the help of Tanmoy Dalui, Roma Sinha and Sonali Das for flow cytometric study. We are grateful to Asim Azhar Siddiqui for the microscopic study. We are also grateful to Pradyot Bhattacharya, Mithun Maji, Somsubahra Thakur Chowdhry and Manjarika De for discussion on the manuscript. We thank Dr. Samit Chattopadhyay, Director IICB, for supporting this work.

**Author contributions**

Conceptualization: MS MA NA.
Data curation: MS MA BJ NA.
Formal analysis: MS BJ MA MK NA.
Funding acquisition: NA.
Investigation: MS BJ MD MA MK.
Methodology: MS BJ MA MD MK.
Project administration: NA.
Resources: NA.
Software: MS MA.
Supervision: NA.
Validation: MS MA BJ MK MD.
Visualization: MS MA BJ MD MK NA.
Writing – original draft: MS NA.
Writing – review & editing: MS BJ MA MK MD NA.

References
1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671. Epub 2012/06/14. doi: 10.1371/journal.pone.0035671 PMID: 22693548
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366(9496):1561–77. Epub 2005/11/01. doi: 10.1016/S0140-6736(05)67629-5 PMID: 16257344
3. Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther. 2010; 8(8):919–44. Epub 2010/08/11. doi: 10.1586/eri.10.78 PMID: 20695748
4. Sundar S, Chakravarty S, Ali N. Current diagnosis and treatment of visceral leishmaniasis: dose and response. J Glob Infect Dis. 2010; 2(2):159–66. Epub 2010/07/08. doi: 10.4103/0974-777X.62886 PMID: 20680972
5. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (Ambisome). J Infect. 1996; 32(2):133–7. Epub 1996/03/01. PMID: 8708370
6. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis. 2003; 16(5):397–401. Epub 2003/09/23. PMID: 14501991
7. Salih NA, van Griensven J, Chappuis F, Antiferens A, Mumina A, Hammam O, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease? Trop Med Int Health. 2014; 19(2):146–52. Epub 2014/01/18. doi: 10.1111/tmi.12238 PMID: 24433217
8. Asad M, Bhattacharya P, Banerjee A, Ali N. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOIME10, a new liposomal amphotericin B. BMC Infect Dis. 2015; 15:188. Epub 2015/04/16. doi: 10.1186/s12879-015-0298-6 PMID: 25884796
9. Mishra J, Dey A, Singh N, Sornvanshi R, Singh S. Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. Indian J Med Res. 2013; 137(4):767–76. Epub 2013/05/25. PMID: 23703346
10. Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet M, Dumon H. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob Chemother. 1999; 44(1):71–6. Epub 1998/08/25. PMID: 10459812
11. Boswell GW, Buel D, Bekersky I. Ambisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol. 1998; 38(7):583–92. Epub 1998/08/14. PMID: 9702642
12. Saar Y, Ransford A, Waldman E, Mazareb S, Amin-Spector S, Plumlee J, et al. Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol Biochem Parasitol. 1998; 95(1):9–20. Epub 1998/10/08. PMID: 9763285
13. Shimasaki H. Assay of fluorescent lipid peroxidation products. Methods Enzymol. 1994; 233:338–46. Epub 1994/01/01. PMID: 8015468

14. Sardar AH, Das S, Agnihotri S, Kumar M, Ghosh AK, Abhishek K, et al. Spinigerin induces apoptotic like cell death in a caspase independent manner in Leishmania donovani. Exp Parasitol. 2013; 135 (4):715–25. Epub 2013/11/05. doi: 10.1016/j.exppara.2013.10.011 PMID: 24184774

15. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145–60. Epub 2005/02/03. doi: 10.1038/nrd1632 PMID: 15688077

16. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010; 27(5):796–810. Epub 2010/03/06. doi: 10.1007/s11095-010-0073-2 PMID: 20204471

17. Lang T, Helio R, Kaye PM, Antoine JC. Leishmania donovani-infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation. J Cell Sci. 1994; 107(Pt 8):2137–50. Epub 1994/08/01.

18. Kroemer G, Galluzzi L, Vandenaebbele P, Abrams J, Alnemri ES, Baerecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009; 16(1):3–11. Epub 2008/10/11. doi: 10.1038/cdd.2008.150 PMID: 18846107

19. Mourdjeva M, Kyurkchiev D, Mandinova A, Altankova I, Kehayov I, Kyurkchiev S. Dynamics of membrane translocation of phosphatidylserine during apoptosis detected by a monoclonal antibody. Apoptosis. 2005; 10(1):209–17. Epub 2005/02/16. doi: 10.1007/s10495-005-6076-5 PMID: 15711937

20. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995; 184(1):39–51. Epub 1995/07/17. PMID: 7622868

21. Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003; 10(6):709–17. Epub 2003/05/23. doi: 10.1038/sj.cdd.4401231 PMID: 12761579

22. Mathur A, Hong Y, Kemp BK, Barrientos AA, Erusalimsky JD. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res. 2000; 46(1):126–38. Epub 2000/03/23. PMID: 10727661

23. Fernie AR, Carrari F, Sweetlove LJ. Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol. 2004; 7(3):254–61. Epub 2004/05/12. doi: 10.1016/j.pbi.2004.03.007 PMID: 15134745

24. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res. 2012; 111(9):1198–207. Epub 2012/10/16. doi: 10.1161/CIRCRESAHA.112.268946 PMID: 23065343

25. Circu ML, Aw TY. Glutathione and apoptosis. Free Radic Res. 2008; 42(8):689–706. Epub 2008/08/02. doi: 10.1080/10715760802317663 PMID: 18671159

26. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014; 2014:360438. Epub 2014/07/08. doi: 10.1155/2014/360438 PMID: 24999379

27. McIwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013; 5(4):a008656. Epub 2013/04/03. doi: 10.1101/cshperspect.a008656 PMID: 23545416

28. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000; 256(1):12–8. Epub 2000/03/31. doi: 10.1006/excr.2000.4834 PMID: 10739646

29. Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000; 102(1):55–66. Epub 2000/08/10. PMID: 10929713

30. Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, et al. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun. 2002; 70(7):3727–35. Epub 2002/06/18. doi: 10.1128/IAI.70.7.3727-3735.2002 PMID: 12065515

31. Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol. 1998; 28(1):121–34. Epub 1998/03/21. PMID: 9504340

32. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev. 1996; 9(4):512–31. Epub 1996/10/01. PMID: 8894350

33. Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother. 1996; 37(3):519–33. Epub 1996/03/01. PMID: 9182109

34. Lee N, Bertholet S, Debrabant A, Muller J, Duncan R, Nakhisi HL. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ. 2002; 9(1):53–64. Epub 2002/01/23. doi: 10.1038/sj.cdd.4400952 PMID: 11803374
A new liposomal amphotericin B as antileishmanial
54. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010; 48(6):749–62. Epub 2010/01/05. doi: 10.1016/j.freeradbiomed.2009.12.022 PMID: 20045723

55. Roy A, Ganguly A, BoseDasgupta S, Das BB, Pal C, Jaisankar P, et al. Mitochondria-dependent reactive oxygen species-mediated programmed cell death induced by 3, 3′-dindolylmethane through inhibition of FO1F1-ATP synthase in unicellular protozoan parasite Leishmania donovani. Mol Pharmacol. 2008; 74(5):1292–307. Epub 2008/08/16. doi: 10.1124/mol.108.050161 PMID: 18703668

56. Mehta A, Shaha C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J Biol Chem. 2004; 279(12):11798–813. Epub 2003/12/18. doi: 10.1074/jbc.M309341200 PMID: 15118764

57. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004; 5(11):897–907. Epub 2004/11/03. doi: 10.1038/nrm1496 PMID: 15520809

58. Sen N, Das BB, Ganguly A, Mukherjee T, Tripathi G, Bandyopadhyay S, et al. Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ. 2004; 11(8):924–36. Epub 2004/05/01. doi: 10.1038/sj.cdd.4401435 PMID: 15118764

59. Debrabant A, Lee N, Bertholet S, Duncan R, Nakhasi HL. Programmed cell death in trypanosomatids and other unicellular organisms. Int J Parasitol. 2003; 33(3):257–67. Epub 2003/04/03. PMID: 12670511

60. Mojc M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, et al. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Mol Pharmacol. 2012; 82(4):700–10. Epub 2012/07/17. doi: 10.1124/mol.112.077842 PMID: 22798453

61. Cohen-Sfady M, Pevsner-Fischer M, Margaliot R, Cohen IR. Heat shock protein 60, via MyD88 innate signaling, protects B cells from apoptosis, spontaneous and induced. J Immunol. 2009; 183(2):890–6. Epub 2009/06/30. doi: 10.4049/jimmunol.0804238 PMID: 19561102

62. Gannavaram S, Debrabant A. Programmed cell death in Leishmania: biochemical evidence and role in parasite infectivity. Front Cell Infect Microbiol. 2012; 2:95. Epub 2012/08/25. doi: 10.3389/fcimb.2012.00095 PMID: 22919685

63. Uren AG, O’Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, et al. Identification of para-caspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell. 2000; 6(4):961–7. Epub 2000/11/25. PMID: 11090634

64. González IJ, Desponds C, Schaff C, Mottram JC, Fasel N. Leishmania major metacaspase can replace yeast metacaspase in programmed cell death and has arginine-specific cysteine peptidase activity. Int J Parasitol. 2007; 37(2):161–72. Epub 2006/11/17. doi: 10.1016/j.ijpara.2006.10.004 PMID: 17107676

65. Waterhouse NJ, Finucane DM, Green DR, Elce JS, Kumar S, Alnemri ES, et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ. 1998; 5(12):1051–61. Epub 1999/01/23. doi: 10.1038/sj.cdd.4400425 PMID: 9894612

66. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methylketone peptide inhibitors of caspases. FEBS Lett. 1999; 442(1):117–21. Epub 1999/01/29. PMID: 9923616

67. Zanger H, Mottram JC, Fasel N. Cell death in Leishmania induced by stress and differentiation: programmed cell death or necrosis? Cell Death Differ. 2002; 9(10):1126–39. Epub 2002/09/17. doi: 10.1038/sj.cdd.4401071 PMID: 12232801

68. Chowdhury S, Mukherjee T, Mukhopadhyay R, Mukherjee B, Sengupta S, Chattopadhyay S, et al. The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice. EMBO Mol Biol. 2012; 4(10):1126–43. Epub 2012/10/03. doi: 10.1002/emmb.201201316 PMID: 23027614

69. Lee N, Gannavaram S, Selvapandian A, Debrabant A. Characterization of metacaspases with trypsin-like activity and their putative role in programmed cell death in the protozoan parasite Leishmania. Eukaryot Cell. 2007; 6(10):1745–57. Epub 2007/08/24. doi: 10.1128/EC.00123-07 PMID: 17715367

70. Shibuya-Fujiiwa N, Hiyazama F, Ogata Y, Ikeda H, Ikekuchi K. Phagocytosis in vitro of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors. Life Sci. 2001; 70(3):291–300. Epub 2002/05/16. PMID: 12006262

71. Nagao G, Ishii K, Hirotta K, Makino K, Terada H. Role of lipid rafts in phagocytic uptake of polystyrene latex microspheres by macrophages. Anticancer Res. 2010; 30(8):3167–76. Epub 2010/09/28. PMID: 20871036

72. Persaud-Sawin DA, Banach L, Harry GJ. Raft aggregation with specific receptor recruitment is required for microphilagocytosis of Abeta42. Glia. 2009; 57(3):320–35. Epub 2008/08/30. doi: 10.1002/glia.20759 PMID: 18756527
73. Sinha R, Roychoudhury J, Palit P, Ali N. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Antimicrob Agents Chemother. 2015; 59(1):344–55. Epub 2014/11/05. doi: 10.1128/AAC.03305-14 PMID: 25367907